Background
==========

Invasive fungal infection (IFI) is a major cause of morbidity and mortality in patients who are immunocompromised, such as those with hematological malignancies or neutropenia due to anticancer chemotherapy or immunosuppression in human stem cell transplantation \[[@b1-medscimonit-24-5258]--[@b3-medscimonit-24-5258]\], with IFI manifesting primarily as pulmonary disease. Delays in treatment of IFI contribute to poor prognosis \[[@b4-medscimonit-24-5258]--[@b6-medscimonit-24-5258]\], but early detection of IFI is often confounded by variability in clinical presentation and a lack of optimal diagnostic criteria \[[@b7-medscimonit-24-5258]\].

In 2008, the Consensus Group formed by the Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC) and the Mycoses Study Group of the National Institute of Allergy and Infectious (MSG) revised the criteria for defining the *proven*, *probable*, and *possible* diagnostic categories for IFI \[[@b8-medscimonit-24-5258]\]. Nevertheless, the current guidelines for the management of IFI are inadequate for unclassified IFI cases. Beside the classification into possible, probable, and proven IFIs, categorizations into the groups A, B, C, D and E, in which patients of the group A have no signs of infections and group B patients develop only persistent febrile neutropenia, whereas group D comprise the probable and group E the proven cases with clear medication indications, have been proposed. Group C has been divided into C-I to C-IV subgroups, and group IV including the possible cases \[[@b9-medscimonit-24-5258]\] ([Supplementary Table 1](#s1-medscimonit-24-5258){ref-type="supplementary-material"}). However, these revisions failed to address the lack of medical evidence-based guidelines for the diagnostic-driven interventions in the B and C-I, C-II, and C--III unclassified categories, which do not meet EORTC/MSG criteria \[[@b10-medscimonit-24-5258]\]. Furthermore, the absence of clear, objective diagnostic criteria for these categories confounds the interpretation of the findings of clinical drug trials of antimicrobials for IFI management because only patients meeting the definitions of possible (C-IV), probable, and proven IFI are included in intervention groups \[[@b7-medscimonit-24-5258]\].

In previous studies, approaches for the treatments of IFIs in patients with hematological malignancies have been proposed, in which the treatments are guided only by risk factors reported in previous studies for specific hematological malignancies \[[@b11-medscimonit-24-5258]\] and another study indicated that febrile neutropenia alone should be an indication for empirical or pre-emptive antifungal therapies \[[@b12-medscimonit-24-5258]\]. Given the difficulty clinicians face in obtaining definitive radiological or laboratory evidence for possible IFI diagnosis, effective diagnostic-driven interventions in unclassified cases is critical for the prevention of IFI progression. As a result, physicians might wish to use a pre-emptive antimicrobial therapy for the treatment of unclassified IFI cases that do not fully satisfy the diagnostic EORTC/MSG criteria \[[@b9-medscimonit-24-5258],[@b10-medscimonit-24-5258],[@b13-medscimonit-24-5258]\].

Caspofungin is an echinocandin, which specifically inhibits fungal 1,3-β glucan synthase, thereby compromising the fungal cell wall integrity \[[@b14-medscimonit-24-5258]\], and it is recommended as empirical therapy in febrile neutropenic patients \[[@b15-medscimonit-24-5258]\].

A recent Chinese large-scale, observational study of antifungal therapy in hematological diseases revealed that in 1401 patients undergoing hematopoietic stem cell transplantation (HSCT), the most common medications for invasive fungal diseases were triazoles (mainly fluconazole) and echinocandins \[[@b16-medscimonit-24-5258]\] and a Chinese guideline for treatment of invasive fungal infection after burn injury recommends azoles and candins as first-line treatment for empirical therapies and excludes polyenes for prophylaxis \[[@b17-medscimonit-24-5258]\]. Another guideline for the management of candidiasis from the Infectious Diseases Society of America (IDSA) recommends caspofungin and azoles as first-line treatments when azole resistance is unlikely \[[@b18-medscimonit-24-5258]\]. However, caspofungin has fewer drug interactions and adverse effects than triazoles and polyene \[[@b19-medscimonit-24-5258]--[@b21-medscimonit-24-5258]\] antimycotics, though it has usage limitations in China due to cost-related issues \[[@b13-medscimonit-24-5258]\]. Caspofungin as a first-line treatment for proven, probable, and possible IFI cases has been reported to have favorable response rates of 56.5% to 66.7% \[[@b22-medscimonit-24-5258]--[@b24-medscimonit-24-5258]\] when caspofungin was used alone, and favorable response rates of 56.3% to 62.5% when it was used in combination therapy with voriconazole \[[@b22-medscimonit-24-5258],[@b23-medscimonit-24-5258]\].

Because there is little information about unclassified IFI evidence-based medications and there is no guideline concerning different subclasses of unclassified IFIs, we conducted this research in order to strengthen the current guidelines for the effective management of unclassified IFIs in immunocompromised patients who fail to satisfy the EORTC/MSG diagnostic criteria for possible, probable, or proven IFI, and we retrospectively performed a multicenter, observational study in China to evaluate the efficacy of caspofungin in hematological patients with unclassified IFI.

Material and Methods
====================

This retrospective, single-arm, multicenter (11 institutions), observational study of the efficacy of caspofungin in 704 immunocompromised patients with hematological malignancies was conducted in China from April 2014 to January 2015. Our study was performed according to the International Conference on Harmonization guidelines on Good Clinical Practice and the Declaration of Helsinki (2004) and was approved by the Ethics Committee of each participating institution. Written informed consent was obtained from each patient prior to our study. Patients' medical charts were reviewed, and those meeting the current EORTC/MSG diagnostic criteria for proven, probable, or possible IFI were excluded from our study, while the remaining patients were categorized as unclassified IFI cases. In the present study, the unclassified cases were divided into group A (n=401) and group B (n=181). Both groups had clinical pulmonary symptoms (cough, chest tightness, hemoptysis, expectoration, chest pain, or dyspnea) and radiographic signs consisting of infiltrates and shadows not concordant with current EORTC/MSG diagnostic criteria. Patients without microbiological or biomarker results were assigned to group A, while patients positive for biomarkers and with positive microscopic examination or positive sputum culture were assigned to group B \[[@b25-medscimonit-24-5258]\].

Treatments and definition of treatment responses
------------------------------------------------

All included patients received caspofungin as mono- or combination therapy for ≥7 days. Other treatments are listed in [Table 1](#t1-medscimonit-24-5258){ref-type="table"}. Complete response (CR) was defined as resolution of all attributable symptoms and signs of pulmonary infection and radiological abnormalities. Partial response (PR) was defined by a substantial reduction of attributable symptoms and signs of pulmonary infection and radiological abnormalities (\>50%). Stable disease (SD) was defined as minimal or no reduction of attributable symptoms and signs of pulmonary infection and radiological abnormalities. Failure was defined as worsening of pre-treatment signs and symptoms of pulmonary infection or radiological abnormalities. Favorable response was defined as complete or partial response. Unfavorable response was defined as SD, failure, or death due to any cause. Caspofungin efficacy was evaluated after ≥7 days of caspofungin monotherapy or combination therapy with any other antifungal agent.

Microbiology factor evidences to diagnose IFI
---------------------------------------------

Samples were obtained from needle aspiration or biopsy, pleural liquid, BALF, bronchial brush, and sputum, as well as peripheral blood, and used for cytological identification, direct microscopy, or culture and other indirect tests, including galactomannan antigen (GM-test) and β-D-glucan (G-test) tests.

Statistical analyses
--------------------

The statistical analysis was performed using the SPSS, version 13.0, software (IBM, Armonk, NY, USA). Descriptive analyses of the patient characteristics and clinical data were performed, with the analysis of treatment outcome stratified based on diagnostic group and treatment regimen. Univariate and multivariate analyses were performed to identify factors associated with favorable outcome in the overall patient sample (A and B groups). The level of statistical significance for the various analyses was set at *P*\<0.05.

Results
=======

Of the 704 hematology patients evaluated, 122 of them received a diagnosis of proven, probable, or possible IFI according to the current EORTC/MSG diagnostic criteria. Of the remaining 582 unclassified IFI cases, 401 (68.9%) patients were assigned to the A group and 181 (31.1%) patients were assigned to the B group.

The mean age of the study sample was 46.1±16.4 years, and 356 (61.2%) of the patients were men ([Table 1](#t1-medscimonit-24-5258){ref-type="table"}). Hematological malignancies included acute myelocytic leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, aplastic anaemia, myelodysplastic syndrome, acute promyelocytic leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia. Most (81.8%) of the patients had Eastern Cooperative Oncology Group (ECOG) scores of 0 to 2.

Hematopoietic stem cell transplantation was used for 13.2% and anticancer chemotherapy for 33.3% of the patients, whereas 53.4% of them had undergone immunosuppressive, anti-infection or symptomatic and supportive care, and a few other secondary treatments.

Although most of the patients (54.2%) were mildly neutropenic (ANC=1000 to 1500/mm^3^) before caspofungin treatment, 35.1% of them were severely neutropenic before treatment. However, group A and B only had significant difference in their HSCT origin and the numbers of patients with antibiotic therapy in the previous 2 weeks or fungal infection in the previous 6 months, but the patients in group A had no microbiology findings ([Table 1](#t1-medscimonit-24-5258){ref-type="table"}).

Cough, chest tightness, and expectoration were the most common clinical features, occurring in 41.8%, 14.6%, and 29.6% of the overall patient sample, respectively. Changes in computed tomography (CT) images (513) were much more common than changes in chest radiographs (114), occurring in 88.1% versus 19.6% of the overall patient sample, respectively. Marker tests revealed that of the tested patients (n=52), 67.3% were positive for galactomannan (GM) and (n=117) 85.5% for (1--3)-β-D-glucan (G). Positive germ-free sites and other side cultures were positive in 39.8% of the group B patients ([Table 2](#t2-medscimonit-24-5258){ref-type="table"}).

In the analysis of caspofungin efficacy, the rates of favorable outcomes were 57.0% for all caspofungin regimens, including 58.6% in group A and 53.6% in group B, and 57.7% favorable outcomes rate for caspofungin as first-line combination therapy, including 56.7% for first-line monotherapy and 65.1% for the first-line combination therapy. Interestingly, the favorable outcomes as first-line monotherapy (51.9%) seemed to be lower than favorable outcomes as first-line combination therapy (90%) in group B patients, but the difference was not significant (*P*=0.3073) due to the small sample size. Similar results of favorable outcome rates were obtained with caspofungin as salvage therapy whether used as mono- or combination therapy. However, these results suggest that caspofungin was effective for treating unclassified IFI cases ([Table 3](#t3-medscimonit-24-5258){ref-type="table"}).

Of the 582 patients with unclassified IFIs, 58 patients died, from which 32 (5.5%) cases were unrelated to the IFIs (cerebral hemorrhage, intracranial hemorrhage, renal failure and gastrointestinal bleeding) and 26 (4.47%) were related to the IFIs.

All of the variables presented in [Table 1](#t1-medscimonit-24-5258){ref-type="table"} and the radiological/clinical symptoms presented in [Table 2](#t2-medscimonit-24-5258){ref-type="table"} were subjected to univariate analysis to identify those associated with favorable clinical outcome ([Supplementary Table 2](#s2-medscimonit-24-5258){ref-type="supplementary-material"}), and those that demonstrated a significant association were included in the multivariate analysis. The results of the multivariate analysis showed that OR values were 0.54 (0.35--0.85), *P*=0.0076 for ECOG scores, 0.56 (0.35--0.89), *P*=0.0140 for cardiovascular disease and 0.26 (0.10--0.72), *P*=0.0098 for hemoptysis, which suggested that these factors were associated with reduced favorable response to caspofungin. Cough, absolute neutrophil count (ANC) \>1000/mm^3^ before antifungal therapy, and ANC \<1000/mm^3^ before antifungal therapy with recovery after treatment (versus ANC\<1000/mm^3^ before antifungal therapy without recovery) were significantly associated with improved clinical outcome in unclassified IFI cases following caspofungin treatment ([Table 4](#t4-medscimonit-24-5258){ref-type="table"}).

These results suggest that an index based on ECOG score, cardiovascular disease, cough, and/or hemoptysis might be useful for identifying unclassified IFI cases who will respond favorably to caspofungin monotherapy and combination therapy regimens. Cough was a beneficial factor, whereas elevated ECOG score and prolonged low ANC counts, as well as hemoptysis and cardiovascular diseases, were unfavorable factors.

Discussion
==========

We retrospectively evaluated the efficacy of caspofungin treatment in a cohort of unclassified IFI cases in China who did not satisfy the EORTC/MSG diagnostic criteria for proven, probable, or possible IFI. To the best of our knowledge, this is the first Chinese study to examine caspofungin efficacy in this patient subpopulation, although the EORTC/MSG definitions are not meant to be used to guide clinical practice \[[@b8-medscimonit-24-5258]\]. A French study including hematological malignancies, HSCT recipients, and neutropenic patients revealed 25% unclassified IFD cases at the beginning of the study, with a 12-week mortality rate of 12%, which was close to that of possible IFD patients \[[@b26-medscimonit-24-5258]\]. Another Chinese study on unclassified IFDs in leukemia patients similarly reported a mortality rate of 11.3% \[[@b27-medscimonit-24-5258]\], which is close to our study with 10% overall and 4.47% IFI-related mortalities.

The univariate and multivariate analyses of our study suggested that an index consisting of ECOG score, cardiovascular disease, cough, and hemoptysis might be useful for identifying unclassified IFI cases who will respond favorably to caspofungin treatment. Factors associated with higher ECOG score, cardiovascular disease, respiratory, hepatic disease, chest tightness, treatment types except HSCT and chemotherapy, as well as hemoptysis, might be expected to be associated with unfavorable clinical outcomes, while cough, ANC \<1000/mm^3^ before antifungal therapy with recovery after treatment and ANC \>1000/mm^3^ before antifungal therapy were associated with favorable response of unclassified IFI patients to caspofungin treatment. Previous studies of possible, probable, and proven IFI in immunocompromised patients have found that ANC recovery was associated with favorable IFI outcome \[[@b28-medscimonit-24-5258]--[@b30-medscimonit-24-5258]\]. Despite our finding that ANC recovery (\>1000/mm^3^) was a significant prognostic factor for caspofungin response in unclassified IFI patients, we have also found ANC recovery to be a useful indicator of the status of antifungal treatment in clinical practice, and caspofungin is the currently recommended antimicrobial for treating IFI in neutropenic patients \[[@b18-medscimonit-24-5258]\]. The association of favorable outcome and cough seems less straightforward. It is possible that coughing may have greater influence on a physician's assessment of pulmonary involvement due to greater prominence in clinical presentation. Our findings suggest that future studies of these factors as prognostic indicators of caspofungin response might be beneficial with regard to treating unclassified IFI in immunocompromised patients who do not satisfy the EORTC/MSG diagnostic criteria for proven, probable, or possible IFI.

Our findings are subject to certain limitations. Although our IFI cohort included 582 patients, several of the treatment regimen subgroups in the analysis of caspofungin efficacy were much smaller, with only 9 and 1 patients in the favorable and unfavorable outcome groups, respectively, for first-line caspofungin combination therapy ([Table 3](#t3-medscimonit-24-5258){ref-type="table"}). Furthermore, it is possible that some of the patients who lacked microbiological data may have had undiagnosed bacterial or viral infections, which would have contributed to an artificially lowered rate of favorable response to caspofungin treatment.

Conclusions
===========

The overall favorable outcome of caspofungin treatment was 57.0% with 56.7% for first-line monotherapy and 65.1% for first-line combination therapy in hematological malignancy patients with unclassified IFDs. Our finding that cough, ANC count and ANC recovery, cardiovascular disease, ECOG score, as well as hemoptysis, might be a useful index for identifying unclassified IFI cases who will respond to caspofungin monotherapy and combination therapy regimens is clinically noteworthy because it helps to fill the existing gap in the medical evidence-based guidelines for treating unclassified IFI patients.

Supplementary Tables
====================

###### 

Classification of IFDs in patients with hematological malignancies proposed by Maertens at al. (2012) \[[@b9-medscimonit-24-5258]\].

                                             A              B                                C                                             D                                                                     E                                                                                                                                                                                                   
  ------------------------------------------ -------------- -------------------------------- --------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- -------------------------- --------------------------------------------- -------------------------------------------------
  Radiological signs and clinical symptoms   No             Persistent febrile neutropenia   No                                            Clinical (any new infiltrate not fulfilling the EORTC/MSG criteria)   Radiological signs on CT (dense, well-circumscribed lesion(s) with or without a halo sign, air-crescent sign, or cavity)   Not considered necessary                                                 
  Mycology results                           Negative       Negative                         Positive biomarker or microscopy or culture   Negative                                                              Positive biomarker or microscopy or culture                                                                                Negative                   Positive biomarker or microscopy or culture   Positive tissue or specimen from a sterile site
  Clinical evidence of IFD                   No             No                               No                                            No                                                                    No                                                                                                                         Yes                        Yes                                           Yes
  Mycological evidence of IFI                No             No                               Yes                                           No                                                                    Yes                                                                                                                        No                         Yes                                           Yes
  Final diagnosis                            Unclassified   Possible IMD                     Probable IMD                                  Proven IMD                                                                                                                                                                                                                                                                
  Management                                 Prophylaxis    Empirical therapy                Diagnostic-driven (pre-emptive) therapy       Targeted therapy                                                                                                                                                                                                                                                          

###### 

Univariate analysis to identify factors associated with favorable outcome to caspofungin treatment for suspected invasive fungal infection.

  Variable                                                                     Unfavorable (stable disease or failure)   Favorable (complete or partial)   OR (95% CI)                    *P*-value
  ---------------------------------------------------------------------------- ----------------------------------------- --------------------------------- ------------------------------ -----------
  Age (y)                                                                      47.5±16.8                                 45.0±16.1                         0.99 (0.98--1.00)              0.0764
  Sex                                                                                                                                                                                     
   Female                                                                      103 (45.6)                                123 (54.4)                        1.0                            0.3092
   Male                                                                        147 (41.3)                                209 (58.7)                        1.19 (0.85--1.67)              
  BMI (kg/m^2^)                                                                18.1±8.3                                  19.5±17.9                         1.01 (0.99--1.02)              0.2984
  Haematopathy                                                                                                                                                                            
   All malignancies                                                            44 (41.1)                                 63 (58.9)                         1.0                            
   Acute myelocytic leukaemia                                                  109 (44.7)                                135 (55.3)                        0.87 (0.55--1.37)              0.5370
   Acute lymphoblastic leukaemia                                               4 (33.3)                                  8 (66.7)                          1.40 (0.40--4.93)              0.6033
   Non-Hodgkins lymphoma                                                       30 (57.7)                                 22 (42.3)                         0.51 (0.26--1.00)              0.0508
   Multiple myeloma                                                            2 (66.7)                                  1 (33.3)                          0.35 (0.03--3.97)              0.3963
   Aplastic anaemia                                                            6 (37.5)                                  10 (62.5)                         1.16 (0.39--3.44)              0.7834
   Myelodysplastic syndrome                                                    18 (46.1)                                 21 (53.9)                         0.82 (0.39--1.70)              0.5865
   Acute promyelocytic leukaemia                                               0 (0.0)                                   1 (100.0)                         \>999.99 (\<0.001--\>999.99)   0.9863
   Chronic myelogenous leukaemia                                               12 (25.5)                                 35 (74.5)                         2.04 (0.95--4.36)              0.0667
   Chronic lymphocytic leukaemia                                               19 (45.2)                                 23 (54.8)                         0.85 (0.41--1.74)              0.6474
   Other malignancies                                                          6 (31.6)                                  13 (68.4)                         1.51 (0.53--4.29)              0.4355
  ECOG score                                                                                                                                                                              
   0--2                                                                        190 (40.3)                                284 (59.7)                        1.0                            
   3--4                                                                        58 (54.7)                                 48 (45.3)                         0.56 (0.37--0.86)              0.0073
  Comorbidities                                                                                                                                                                           
  Endocrine                                                                                                                                                                               
   No                                                                          224 (43.0)                                297 (57.0)                        1.0                            
   Yes                                                                         26 (42.6)                                 35 (57.4)                         1.02 (0.59--1.74)              0.9558
  Cardiovascular                                                                                                                                                                          
   No                                                                          199 (40.6)                                291 (59.4)                        1.0                            
   Yes                                                                         51 (55.4)                                 41 (44.6)                         0.55 (0.35--0.86)              0.0090
  Respiratory                                                                                                                                                                             
   No                                                                          228 (41.8)                                317 (58.2)                        1.0                            0.0394
   Yes                                                                         22 (59.5)                                 15 (40.5)                         0.49 (0.25--0.97)              
  Congenital                                                                                                                                                                              
   No                                                                          250 (43.0)                                332 (57.0)                                                       
   Yes                                                                         0 (0.0)                                   0 (0.0)                                                          
  Urogenital                                                                                                                                                                              
   No                                                                          242 (42.6)                                326 (57.4)                        1.0                            
   Yes                                                                         8 (57.1)                                  6 (42.9)                          0.56 (0.19--1.63)              0.2841
  Renal                                                                                                                                                                                   
   No                                                                          235 (42.3)                                320 (57.7)                        1.0                            
   Yes                                                                         15 (55.6)                                 12 (44.4)                         0.59 (0.27--1.28)              0.1800
  Gastroesophageal                                                                                                                                                                        
   No                                                                          241 (42.6)                                324 (57.4)                        1.0                            
   Yes                                                                         9 (52.9)                                  8 (47.1)                          0.66 (0.25--1.74)              0.4016
  Hepatic                                                                                                                                                                                 
   No                                                                          218 (41.4)                                309 (58.6)                        1.0                            
   Yes                                                                         32 (58.2)                                 23 (41.8)                         0.51 (0.29--0.89)              0.0181
  Solid tumor                                                                                                                                                                             
   No                                                                          247 (42.7)                                331 (57.3)                        1.0                            
   Yes                                                                         3 (75.0)                                  1 (25.0)                          0.25 (0.03--2.41)              0.2297
  Others                                                                                                                                                                                  
   No                                                                          226 (43.5)                                293 (56.5)                        1.0                            
   Yes                                                                         24 (38.1)                                 39 (61.9)                         1.25 (0.73--2.15)              0.4100
  Treatment type                                                                                                                                                                          
   HSCT                                                                        26 (33.8)                                 51 (66.2)                         1.0                            
   Chemotherapy                                                                78 (40.2)                                 116 (59.8)                        0.76 (0.44--1.32)              0.3263
   Other                                                                       146 (47.0)                                165 (53.0)                        0.58 (0.34--0.97)              0.0385
  HSCT type                                                                                                                                                                               
   Autograft                                                                   1 (10.0)                                  9 (90.0)                          1.0                            
   Allograft                                                                   25 (37.3)                                 42 (62.7)                         0.19 (0.02--1.56)              0.1215
  HSCT stem cell derived                                                                                                                                                                  
   Bone marrow + peripheral blood stem cell                                    16 (41.0)                                 23 (59.0)                         1.0                            
   Peripheral blood + others                                                   10 (26.3)                                 28 (73.7)                         1.95 (0.74--5.11)              0.1751
  Chemotherapy type                                                                                                                                                                       
   Intravenous chemotherapy                                                    73 (39.2)                                 113 (60.8)                        1.0                            
   Oral                                                                        5 (62.5)                                  3 (37.5)                          0.39 (0.09--1.67)              0.2037
  Antimicrobial therapy during previous 2 weeks                                                                                                                                           
   No                                                                          30 (37.5)                                 50 (62.5)                         1.0                            
   Yes                                                                         220 (43.8)                                282 (56.2)                        0.77 (0.47--1.25)              0.2895
  Fungal infection during previous 6 months                                                                                                                                               
   No                                                                          152 (41.2)                                217 (58.8)                        1.0                            
   Yes                                                                         46 (44.7)                                 57 (55.3)                         0.87 (0.56--1.35)              0.5285
   Unknown                                                                     52 (47.3)                                 58 (52.7)                         0.78 (0.51--1.20)              0.2582
  Total prenteral nutrition                                                                                                                                                               
   No                                                                          226 (43.0)                                299 (57.0)                        1.0                            
   Yes                                                                         22 (40.0)                                 33 (60.0)                         1.13 (0.64--2.00)              0.6640
  Central vein catheter                                                                                                                                                                   
   No                                                                          140 (46.5)                                161 (53.5)                        1.0                            
   Yes                                                                         108 (38.7)                                171 (61.3)                        1.38 (0.99--1.92)              0.0580
  ANC before antifungal therapy                                                                                                                                                           
   ANC \<500/mm^3^                                                             87 (42.9)                                 116 (57.1)                        1.0                            
   ANC 500--1000/mm^3^                                                         31 (50.0)                                 31 (50.0)                         0.75 (0.42--1.33)              0.3227
   ANC \>1000/mm^3^                                                            129 (41.1)                                185 (58.9)                        1.08 (0.75--1.54)              0.6896
  ANC recovery                                                                                                                                                                            
   No                                                                          51 (58.6)                                 36 (41.4)                         1.0                            
   Yes                                                                         67 (37.6)                                 111 (62.4)                        2.35 (1.39--3.96)              0.0014
  ANC recovery groups                                                                                                                                                                     
   ANC \<1000/mm^3^ before antifungal therapy without recovery                 51 (58.6)                                 36 (41.4)                         1.0                            
   ANC \<1,000/mm^3^ before antifungal therapy with recovery after treatment   67 (37.6)                                 111 (62.4)                        2.35 (1.39--3.96)              0.0014
   ANC \>1,000/mm^3^ before antifungal therapy                                 129 (41.1)                                185 (58.9)                        2.03 (1.25--3.29)              0.0040
  Symptoms                                                                                                                                                                                
  Cough                                                                                                                                                                                   
   No                                                                          162 (47.8)                                177 (52.2)                        1.0                            
   Yes                                                                         88 (36.2)                                 155 (63.8)                        1.61 (1.15--2.26)              0.0055
  Chest tightness                                                                                                                                                                         
   No                                                                          205 (41.3)                                292 (58.7)                        1.0                            
   Yes                                                                         45 (52.9)                                 40 (47.1)                         0.62 (0.39--0.99)              0.0454
  Hemoptysis                                                                                                                                                                              
   No                                                                          237 (42.1)                                326 (57.9)                        1.0                            
   Yes                                                                         13 (68.4)                                 6 (31.6)                          0.34 (0.13--0.90)              0.0292
  Expectoration                                                                                                                                                                           
   No                                                                          180 (43.9)                                230 (56.1)                        1.0                            
   Yes                                                                         70 (40.7)                                 102 (59.3)                        1.14 (0.80--1.64)              0.4762
  Chest Pain                                                                                                                                                                              
   No                                                                          243 (42.8)                                325 (57.2)                        1.0                            
   Yes                                                                         7 (50.0)                                  7 (50.0)                          0.75 (0.26--2.16)              0.5911
  Dyspnoea                                                                                                                                                                                
   No                                                                          225 (42.2)                                308 (57.8)                        1.0                            
   Yes                                                                         25 (51.0)                                 24 (49.0)                         0.70 (0.39--1.26)              0.2352
  Other                                                                                                                                                                                   
   No                                                                          216 (42.1)                                296 (57.8)                        1.0                            
   Yes                                                                         34 (48.6)                                 36 (51.4)                         0.77 (0.47--1.27)              0.3124
  Patient                                                                                                                                                                                 
   C-II                                                                        166 (41.4)                                235 (58.6)                        1.0                            
   C-III                                                                       84 (46.4)                                 97 (53.6)                         0.82 (0.57--1.16)              0.2585
  Fungal infections                                                                                                                                                                       
   No                                                                          237 (43.3)                                310 (56.7)                        1.0                            
   Yes                                                                         13 (37.1)                                 22 (62.9)                         1.29 (0.64--2.62)              0.4747
  Caspofungin as first-line therapy                                                                                                                                                       
   No                                                                          105 (43.9)                                134 (56.1)                        1.0                            
   Yes                                                                         145 (42.3)                                198 (57.7)                        1.07 (0.77--1.49)              0.6906
  Monotherapy *vs.* combination therapy                                                                                                                                                   
   Caspofungin as a monotherapy agent                                          200 (43.5)                                260 (56.5)                        1.0                            
   Caspofungin as a combination agent                                          50 (41.0)                                 72 (59.0)                         1.11 (0.74--1.66)              0.6208

Unfavorable response was stable disease or treatment failure, and favorable response was complete or partial resolution. Values for unfavorable and favorable response categories are reported as mean ± standard error or the number of observations and percentage. ECOG -- Eastern Cooperative Oncology Group; ANC -- absolute neutrophil count; HSCT -- haematopoietic stem cell transplantation.
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###### 

Characteristics of patients with unclassified invasive fungal infection.

  Variable                                                      Group A       Group B       Total        *P*-value
  ------------------------------------------------------------- ------------- ------------- ------------ -----------
  Case distribution                                             401 (68.9%)   181 (31.1%)   582          --
  Female                                                        158 (39.4)    68 (37.6)     226 (38.8)   0.9953
  Male                                                          243 (60.6)    113 (62.4)    356 (61.2)   
  Age (y)                                                       45.5±16.7     47.4±15.8     46.1±16.4    0.1852
  BMI (kg/m^2^)                                                 18.9±16.6     18.9±8.6      18.9±14.6    0.9570
  Haematopathy                                                                                           
   Acute myelocytic leukaemia                                   164 (40.9)    80 (44.2)     244 (41.9)   0.6135
   Acute lymphoblastic leukaemia                                83 (20.7)     24 (13.3)     107 (18.4)   
   Non-Hodgkins lymphoma                                        32 (8.0)      15 (8.3)      47 (8.1)     
   Multiple myeloma                                             26 (6.5)      13 (7.2)      39 (6.7)     
   Aplastic anaemia                                             28 (7.0)      14 (7.7)      42 (7.2)     
   Myelodysplastic syndrome                                     37 (9.2)      15 (8.3)      52 (8.9)     
   Acute promyelocytic leukaemia                                7 (1.8)       5 (2.8)       12 (2.1)     
   Chronic myelogenous leukaemia                                8 (2.0)       8 (4.4)       16 (2.7)     
   Chronic lymphocytic leukaemia                                2 (0.5)       1 (0.6)       3 (0.5)      
   Other malignancies                                           14 (3.5)      6 (3.3)       20 (3.4)     
  ECOG score                                                                                             
   0--2                                                         323 (80.5)    153 (84.5)    476 (81.8)   0.2493
   3--4                                                         78 (19.5)     28 (15.5)     106 (18.2)   
  Comorbidities                                                                                          
   Endocrine                                                    37 (9.2)      24 (13.3)     61 (10.5)    0.1415
   Cardiovascular                                               61 (15.2)     31 (17.1)     92 (15.8)    0.5577
   Respiratory                                                  29 (7.2)      8 (4.4)       37 (6.4)     0.1981
   Urogenital                                                   9 (2.2)       5 (5.2)       14 (2.4)     0.7057
   Renal                                                        20 (5.0)      7 (3.9)       27 (4.6)     0.5520
   Gastroesophageal                                             15 (3.7)      2 (1.1)       17 (2.9)     0.0805
   Hepatic                                                      41 (10.2)     14 (7.7)      55 (9.5)     0.3419
   Solid tumor                                                  2 (0.5)       2 (1.1)       4 (0.7)      0.4125
   Others                                                       50 (12.5)     13 (7.2)      63 (10.8)    0.0574
  Treatments                                                                                             
   HSCT                                                         48 (12.0)     29 (16.0)     77 (13.2)    0.7147
   Chemotherapy                                                 132 (32.9)    62 (34.3)     194 (33.3)   
   Other interventions                                          221 (55.1)    90 (49.7)     311 (53.4)   
    Immunosuppressive therapy                                   13 (2.2)      5 (0.9)       18 (3.1)     
    Anti-infection therapy                                      144 (24.8)    66 (11.3)     210 (36.1)   
    Symptomatic and supportive care                             56 (9.6)      16 (2.7)      72 (12.4)    
    Other secondary treatments                                  9 (1.5)       3 (0.5)       12 (2.1)     
  HSCT type                                                                                              
   Autograft                                                    8 (16.7)      2 (6.9)       10 (13.0)    0.2166
   Allograft                                                    40 (83.3)     27 (93.1)     67 (87.0)    
  HSCT cell origin                                                                                       
   Bone marrow and peripheral blood                             19 (39.6)     20 (69.0)     39 (50.6)    0.0125
   Peripheral blood and others                                  29 (60.4)     9 (31.0)      38 (49.4)    
  Chemotherapy type                                                                                      
   Intravenous                                                  127 (96.2)    59 (95.2)     186 (95.9)   0.7314
   Oral                                                         5 (3.8)       3 (4.8)       8 (4.1)      
  Antibiotic therapy previous 2 weeks                           338 (84.3)    164 (90.6)    502 (86.3)   0.0404
  Fungal infection previous 6 months                            72 (18.0)     31 (17.1)     103 (17.7)   0.0481
  Total parenteral nutrition                                    41 (10.2)     14 (7.8)      55 (9.5)     0.3615
  Central vein catheter                                         108 (38.7)    171 (61.3)    279 (47.9)   0.0580
  ANC before antifungal therapy                                                                          
   ANC\<500/mm^3^                                               132 (33.0)    71 (39.7)     203 (35.1)   0.1553
   ANC=500--1000/mm^3^                                          48 (12.0)     14 (7.8)      62 (10.7)    
   ANC=1000--1500/mm^3^                                         220 (55.0)    94 (52.5)     314 (54.2)   
  ANC \<500/mm^3^ duration                                                                               
   ≤7 days                                                      59 (44.7)     36 (50.7)     95 (46.8)    0.4133
   \>7 days                                                     73 (55.3)     35 (49.3)     108 (53.2)   
  ANC recovery, No                                              56 (31.1)     31 (36.5)     87 (32.8)    0.3858
  ANC recovery, Yes                                             124 (68.9)    54 (63.5)     178 (67.2)   
  ANC \>1000/mm^3^ before antifungal therapy                    220 (55.0)    94 (52.5)     314 (54.2)   0.5842
  ANC \<1000/mm^3^ before antifungal therapy with recovery      124 (31.0)    54 (30.2)     178 (30.7)   
  ANC \<1000/mm^3^ before antifungal therapy without recovery   56 (14.0)     31 (17.3)     87 (15.0)    

Values are reported as mean ± standard error or the number of observations and percentage. ECOG -- Eastern Cooperative Oncology Group; ANC -- absolute neutrophil count; HSCT -- haematopoietic stem cell transplantation.

###### 

Clinical symptoms, radiological data, and microbiology findings for patients with unclassified invasive fungal infection.

  Clinical data                               Group A (n=401)   Group B (n=181)   Total (n=582)
  ------------------------------------------- ----------------- ----------------- ---------------
  Clinical symptoms                                                               
   Cough                                      159 (39.7)        84 (46.4)         243 (41.8)
   Chest Tightness                            54 (13.5)         31 (17.1)         85 (14.6)
   Hemoptysis                                 13 (3.2)          6 (3.3)           19 (3.3)
   Expectoration                              117 (29.2)        55 (30.4)         172 (29.6)
   Chest Pain                                 11 (2.7)          3 (1.7)           14 (2.4)
   Dyspnoea                                   34 (8.5)          15 (8.3)          49 (8.4)
  Changes in CT                                                                   
   Yes                                        348 (86.8)        165 (91.2)        513 (88.1)
   New infiltration                           348 (86.8)        165 (91.2)        513 (88.1)
  Changes in chest X-ray                                                          
   Yes                                        71 (17.7)         43 (23.8)         114 (19.6)
   Nodule                                     2 (0.5)           1 (0.6)           3 (0.5)
   Patch shadow or effusion                   38 (9.5)          33 (18.2)         71 (12.2)
   Cavity                                     0 (0)             0 (0)             0 (0)
   Pleural effusion                           12 (3.0)          7 (3.9)           19 (3.3)
   Others                                     27 (6.7)          9 (5.0)           36 (6.2)
  Microbiology findings                                                           
   GM test (n=52) positive                    N/A               35 (67.3)         35 (67.3)
   G test (n=117) positive                    0 (0.0)           100 (85.5)        100 (85.5)
   Germ-free sites culture (n=582) positive   0 (0.0)           7 (3.9)           7 (1.2)
   Other sites culture (n=582) positive       0 (0.0)           65 (35.9)         65 (11.2)

###### 

Evaluation of caspofungin therapy in patients with unclassified invasive fungal infection.

  Variable/group                   Case distribution (%)   Duration (days)   Favorable response (%)   *P*-value (favorable response)
  -------------------------------- ----------------------- ----------------- ------------------------ --------------------------------
  All caspofungin regimens                                                                            
   Group A                         401 (68.9)              12.8±16.1         235 (58.6)               0.2582
   Group B                         181 (31.1)              15.2±13.8         97 (53.6)                
   Total                           582                     13.5±15.5         332 (57.0)               
  Caspofungin first-line therapy                                                                      
   Group A                         256 (74.6)              12.8±13.9         149 (58.2)               0.7589
   Group B                         87 (25.4)               17.3±17.5         49 (56.3)                
   Total                           343                     13.6±14.8         198 (57.7)               
  First-line monotherapy                                                                              
   Group A                         223 (74.3)              12.7±14.3         130 (58.3)               0.3325
   Group B                         77 (25.7)               17.3±18.3         40 (51.9)                
   Total                           300                     13.6±15.2         170 (56.7)               
  First-line combination therapy                                                                      
   Group A                         33 (76.7)               13.6±8.4          19 (57.6)                0.0595
   Group B                         10 (23.3)               17.2±12.3         9 (90.0)                 
   Total                           43                      14.6±9.5          28 (65.1)                
  Caspofungin salvage therapy                                                                         
   Group A                         145 (60.7)              13.0±20.8         86 (59.3)                0.2096
   Group B                         94 (39.3)               13.5±9.3          48 (51.1)                
   Total                           239                     13.2±16.9         134 (56.1)               
  Salvage monotherapy                                                                                 
   Group A                         113 (58.8)              13.1±22.2         65 (57.5)                0.5497
   Group B                         79 (41.2)               13.0±7.7          42 (53.2)                
   Total                           192                     13.1±17.8         107 (55.7)               
  Salvage combination therapy                                                                         
   Group A                         32 (68.1)               12.3±6.8          21 (65.6)                0.0977
   Group B                         15 (31.9)               15.6±14.4         6 (40.0)                 
   Total                           47                      14.0±11.2         27 (57.5)                

Values are presented as the number of observations and percentage or as the median ± interquartile range.

###### 

Multivariate analysis to identify factors associated with favourable outcome to caspofungin treatment for unclassified invasive fungal infection.

  Variable                                                                                                                        OR (95% CI)         *P*-value
  ------------------------------------------------------------------------------------------------------------------------------- ------------------- -----------
  ECOG score                                                                                                                      0.54 (0.35--0.85)   0.0076
  Cardiovascular disease                                                                                                          0.56 (0.35--0.89)   0.0140
  Cough                                                                                                                           1.91 (1.33--2.73)   0.0005
  Hemoptysis                                                                                                                      0.26 (0.10--0.72)   0.0098
  ANC \>1,000/mm^3^ before antifungal treatment[\*](#tfn4-medscimonit-24-5258){ref-type="table-fn"}                               1.91 (1.17--3.13)   0.0103
  ANC \<1,000/mm^3^ before antifungal therapy with recovery after treatment[\*](#tfn4-medscimonit-24-5258){ref-type="table-fn"}   2.35 (1.38--4.03)   0.0018

OR -- odds ratio; CI -- confidence interval; ECOG -- Eastern Cooperative Oncology Group; ANC -- absolute neutrophil count.
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